The effect of racemic gossypol and AT-101 on angiogenic profile of OVCAR-3 cells: a preliminary molecular framework for gossypol enantiomers

dc.contributor.authorVarol, U.
dc.contributor.authorKaraca, B.
dc.contributor.authorTunali, D.
dc.contributor.authorDegirmenci, M.
dc.contributor.authorCirak, Y.
dc.contributor.authorPurcu, D.U.
dc.contributor.authorUzunoglu, S.
dc.contributor.authorSezgin, C.
dc.contributor.authorKarabulut, B.
dc.contributor.authorSanli, U.A.
dc.contributor.authorUslu, R.
dc.date.accessioned2018-06-18T09:46:30Z
dc.date.available2018-06-18T09:46:30Z
dc.date.issued2009
dc.description.abstractTo compare the effect of racemic gossypol with its (–)/(–) enantiomer (AT-101) on expression profiles of angiogenic molecules by mRNA levels in human ovarian cancer cell line OVCAR-3. Methods: Cell viability assay (2,3-bis (2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide) was used to detect cytotoxicity of gossypol enantiomers. DNA fragmentation by an enzyme-linked immunosorbent (ELISA) assay was used to evaluate the rate of apoptosis. The mRNA expression levels of angiogenic molecules were investigated by Human Angiogenesis RT2 ProfilerTM PCR Array (SuperArray, Frederick, MD). Results: Both racemic form and AT-101 resulted in a significant cytotoxicity and induced apoptosis. This effect was observed in a dose- and time dependent manner. However, AT-101 was much more potent. In addition, the treatment of 10 μM of racemic gossypol alone and 3 μM of AT-101 alone resulted in significant down-regulation (≥ 3 fold) in mRNA levels of some pivotal angiogenic molecules in OVCAR-3, but altered gene profiles were different by the treatment of each enantiomer. Conclusion: The efficacy of two gossypol enantiomers in OVCAR-3 cells showed distinction. AT-101 was much more potent than racemic gossypol, not only by means of cell death and apoptosis, but also by modulation of angiogenic molecules released from OVCAR-3 cells. Further studies with endothelial cells should be done to verify the anti-angiogenic effect of gossypol enantiomers in cancer treatment.uk_UA
dc.identifier.citationThe effect of racemic gossypol and AT-101 on angiogenic profile of OVCAR-3 cells: a preliminary molecular framework for gossypol enantiomers / U. Varol, B. Karaca, D. Tunali, M. Degirmenci, Y. Cirak, D.U. Purcu, S. Uzunolgu, C. Sezgin, B. Karabulut, U.A. Sanli, R. Uslu // Experimental Oncology. — 2009. — Т. 31, № 4. — С. 220-225. — Бібліогр.: 34 назв. — англ.uk_UA
dc.identifier.issn1812-9269
dc.identifier.urihttps://nasplib.isofts.kiev.ua/handle/123456789/138141
dc.language.isoenuk_UA
dc.publisherІнститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН Україниuk_UA
dc.relation.ispartofExperimental Oncology
dc.statuspublished earlieruk_UA
dc.subjectOriginal contributionsuk_UA
dc.titleThe effect of racemic gossypol and AT-101 on angiogenic profile of OVCAR-3 cells: a preliminary molecular framework for gossypol enantiomersuk_UA
dc.typeArticleuk_UA

Файли

Оригінальний контейнер

Зараз показуємо 1 - 1 з 1
Завантаження...
Ескіз
Назва:
06-Varol.pdf
Розмір:
151.34 KB
Формат:
Adobe Portable Document Format

Контейнер ліцензії

Зараз показуємо 1 - 1 з 1
Завантаження...
Ескіз
Назва:
license.txt
Розмір:
817 B
Формат:
Item-specific license agreed upon to submission
Опис: